{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:11:01Z","timestamp":1791774661463,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1053\/j.ajkd.2021.09.014","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T02:49:25Z","timestamp":1636166965000},"page":"796-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial"],"prefix":"10.1053","volume":"79","author":[{"given":"Odette S.","family":"Reifsnider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuraag R.","family":"Kansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Koitka-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stargardter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Kuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ustyugova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2021.09.014_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.014_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.014_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.014_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0971-4065.131999","article-title":"Cost of treating diabetic kidney disease","volume":"24","author":"Dasgupta","year":"2014","journal-title":"Indian J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.09.014_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11892-018-0980-x","article-title":"The landscape of diabetic kidney disease in the United States","volume":"18","author":"Duru","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.014_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Diabetes 2030: insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"issue":"22","key":"10.1053\/j.ajkd.2021.09.014_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.014_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.014_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2021.09.014_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2021.09.014_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2021.09.014_bib13","unstructured":"ClinicalTrials.gov. A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (DAPA-CKD). ClinicalTrials.gov Identifier: NCT03036150. Updated May 1, 2020. Accessed June 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036150."},{"key":"10.1053\/j.ajkd.2021.09.014_bib14","unstructured":"ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection with Empagliflozin). ClinicalTrials.gov Identifier: NCT03594110. Updated June 4, 2020. Accessed June 6, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594110."},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.014_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2021.09.014_bib16","doi-asserted-by":"crossref","first-page":"iii193","DOI":"10.1093\/ndt\/gfx145.SP259","article-title":"Effects of empagliflozin on renal outcomes across KDIGO risk categories: results from the EMPA-REG OUTCOME\u00ae trial. Abstract SP259","volume":"32","author":"Wanner","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2021.09.014_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ajkd.2021.09.014_bib18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dme.14076","article-title":"Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial","volume":"36","author":"Kansal","year":"2019","journal-title":"Diabet Med"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.014_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40261-018-0620-x","article-title":"Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece","volume":"38","author":"Gourzoulidis","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1053\/j.ajkd.2021.09.014_bib20","first-page":"43","article-title":"Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study","volume":"18","author":"Iannazzo","year":"2017","journal-title":"Farmeconomia Health Econ Ther Pathways"},{"issue":"10","key":"10.1053\/j.ajkd.2021.09.014_bib21","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.clinthera.2019.07.016","article-title":"Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME Trial","volume":"41","author":"Kaku","year":"2019","journal-title":"Clin Ther"},{"issue":"10","key":"10.1053\/j.ajkd.2021.09.014_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2021.09.014_bib23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archinte.167.11.1130","article-title":"Cardiovascular disease and subsequent kidney disease","volume":"167","author":"Elsayed","year":"2007","journal-title":"Arch Intern Med"},{"issue":"12 suppl","key":"10.1053\/j.ajkd.2021.09.014_bib24","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.014_bib25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.014_bib26","first-page":"1","article-title":"United States Life Tables, 2017","volume":"68","author":"Arias","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2021.09.014_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2016.05.018","article-title":"EQ-5D scores for diabetes-related comorbidities","volume":"19","author":"Sullivan","year":"2016","journal-title":"Value Health"},{"key":"10.1053\/j.ajkd.2021.09.014_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1477-7525-10-99","article-title":"Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study","volume":"10","author":"Grandy","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"10.1053\/j.ajkd.2021.09.014_bib29","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/eurheartj\/ehm020","article-title":"IDEAL Trial Investigators. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin","volume":"28","author":"Lindgren","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ajkd.2021.09.014_bib32","unstructured":"Institute for Clinical and Economic Review (ICER). ICER\u2019s reference case for economic evaluations: principles and rationale. January 31, 2020. Accessed June 14, 2021. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf"},{"key":"10.1053\/j.ajkd.2021.09.014_bib35","unstructured":"Shetty S, Stafkey-Mailey D, Yue B, et\u00a0al. The direct cost of cardiovascular disease-related death in patients with type 2 diabetes mellitus in a commercially insured population in the United States. Presented at: AMCP 2016 Nexus; October 3-6, 2016; National Harbor, MD. https:\/\/www.t2dwithcvd.com\/pdfs\/PC-00198%20AMCP%20Poster%204.1.pdf."},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2021.09.014_bib36","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States","volume":"73(3)","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.014_bib38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/03007995.2019.1708285","article-title":"Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE Clinical Trial","volume":"36","author":"Manceur","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1053\/j.ajkd.2021.09.014_bib39","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/j.jval.2016.09.1882","article-title":"Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada. PDB52 presented at ISPOR Europe 2016","volume":"19","author":"Mettam","year":"2016","journal-title":"Value Health"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2021.09.014_bib40","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.jval.2018.09.768","article-title":"Cost-effectiveness analysis of empagliflozin treatment in patients with type 2 diabetes and chronic heart failure based on subgroup of EMPA-REG OUTCOME in the United Kingdom. PDB63 presented at ISPOR Europe 2018","volume":"21","author":"Reifsnider","year":"2018","journal-title":"Value Health"},{"key":"10.1053\/j.ajkd.2021.09.014_bib41","series-title":"Cost-effectiveness of empagliflozin treatment in patients with type 2 diabetes and chronic heart failure based on a subgroup of EMPA-REG outcome in the United States","author":"Reifsnider","year":"2018"},{"issue":"4","key":"10.1053\/j.ajkd.2021.09.014_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.amepre.2017.11.013","article-title":"Recommendations of the second panel on cost effectiveness in health and medicine: a reference, not a rule book","volume":"54","author":"Carias","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1053\/j.ajkd.2021.09.014_bib43","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Jardiance\u00ae (empagliflozin) [prescribing information]. CT2020. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc."},{"issue":"6","key":"10.1053\/j.ajkd.2021.09.014_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"10.1053\/j.ajkd.2021.09.014_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S2213-8587(18)30263-8","article-title":"New pharmacological strategies for protecting kidney function in type 2 diabetes","volume":"7","author":"Muskiet","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2021.09.014_bib46","first-page":"S135","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1053\/j.ajkd.2021.09.014_bib47","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621009525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621009525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:42:39Z","timestamp":1759462959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621009525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0272638621009525"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.014","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}